Sernova Corp. (T:SVA*CA)
Business Focus: Medical Devices & Implants
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| Company Contact | |
| Address: | 700 Collip Circle, Ste 114 LONDON ON N6G 4X8 |
| Tel: | 1-519-9027923 |
| Website: | https://www.sernova.com |
| IR: | See website |
| Key People | ||
| Brett Whalen Chairman of the Board | Cynthia Pussinen Chief Executive Officer, Director | David C. Swetlow Chief Financial Officer |
| Philip M. Toleikis Chief Technology Officer | Chris Barnes Vice President of Investor Relations | Frank Shannon Vice President - Clinical Development and Regulatory Affairs | Modestus Obochi Chief Business Officer |
| Business Overview |
| Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases. |
| Financial Overview |
| For the three months ended 31 January 2024, Sernova Corp revenues was not reported. Net loss increased 22% to C$9.7M. Higher net loss reflects Consulting and professional fees increase from C$162K to C$692K (expense), Personnel costs increase of 56% to C$865K (expense), Interest income decrease of 64% to C$166K (income). Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.03. |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $114.98M as of Jan 31, 2024 |
| Annual revenue (TTM): | $0.00M as of Jan 31, 2024 |
| EBITDA (TTM): | -$41.48M as of Jan 31, 2024 |
| Net annual income (TTM): | -$40.73M as of Jan 31, 2024 |
| Free cash flow (TTM): | -$29.14M as of Jan 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 303,407,686 as of Mar 13, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.